A Novel Antibody Against the Non–Receptor-Binding Domain Region of Middle East Respiratory Syndrome Coronavirus Spike Protein
The Journal of Infectious Diseases · 2025
DOI: 10.1093/infdis/jiaf202 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von So-Young Lee und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Emerging Virus and Vector Research, Center for Emerging Virus Research, Korea National Institute of Health, Korea Disease Control and Pre…. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, Middle East Respiratory Syndrome Coronavirus, Antibodies, Neutralizing, Antibodies, Viral. Die Arbeit nennt 40 Literaturangaben. Gefördert von: the National Institute of Health.
Abstract (Originalsprache)
The Middle East respiratory syndrome coronavirus (MERS-CoV) was first identified in 2012 and has since spread worldwide. To date, no vaccines or therapeutics against MERS-CoV have been approved for clinical use. The spike protein of MERS-CoV facilitates attachment and fusion with target cell membranes. Therefore, inhibiting S protein attachment represents a key therapeutic strategy for treating early MERS-CoV infection. Herein, we present 7 human neutralizing antibodies (KNIH-58, -68, -72, -78, -88, -90, and -95) against MERS-CoV. KNIH-58 and -68 bound to the receptor-binding subdomain (RBD) of the spike protein, while the other 5 monoclonal antibodies did not. KNIH-88, which targets the non-RBD region, exhibited potent neutralizing activities in vitro and in a transgenic mouse model, with similar results for KNIH-58. Structural analysis of KNIH-88 bound to the spike protein revealed novel epitopes in the non-RBD region. These findings may facilitate therapeutic and prophylactic antibody development against MERS-CoV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Emerging Virus and Vector Research, Center for Emerging Virus Research, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si, Republic of Korea.
- Division of Structural Biology, Baobab AiBIO, Incheon, Republic of Korea.
- Center for Emerging Virus Research, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si, Republic of Korea.
ORCID-Profile: So-Young Lee, Hyunbum Jeon, Da Sol Kim, Hyun-Joo Kim, Kyung-Chang Kim, Joo-Yeon Lee, Kunwoong Park, Youngki Yoo, Kiju Choi, Hansaem Lee
Förderung
- the National Institute of Health
Zitieren
APA
Lee, S. Y., Woo, H. M., Jeon, H., Kim, N., Kim, D. S., Park, C. K., Kim, H. J., Kim, K. C., Lee, J. Y., Park, K., Yoo, Y., Choi, K., & Lee, H. (2025). A Novel Antibody Against the Non–Receptor-Binding Domain Region of Middle East Respiratory Syndrome Coronavirus Spike Protein. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf202
Vancouver
Lee SY, Woo HM, Jeon H, Kim N, Kim DS, Park CK, et al. A Novel Antibody Against the Non–Receptor-Binding Domain Region of Middle East Respiratory Syndrome Coronavirus Spike Protein. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf202
BibTeX
@article{Lee2025,
author = {Lee, So-Young and Woo, Hye-Min and Jeon, Hyunbum and Kim, Nayoung and Kim, Da Sol and Park, Chan Ki and Kim, Hyun-Joo and Kim, Kyung-Chang and Lee, Joo-Yeon and Park, Kunwoong and Yoo, Youngki and Choi, Kiju and Lee, Hansaem},
title = {A Novel Antibody Against the Non–Receptor-Binding Domain Region of Middle East Respiratory Syndrome Coronavirus Spike Protein},
journal = {The Journal of Infectious Diseases},
year = {2025},
doi = {10.1093/infdis/jiaf202}
}
EUVIMED